CClinicalTrials.gg
Not yet recruitingNCT06864689PrEPUpdated Sep 4, 2026

Leveraging Video Logs as a Bridge to Pre-exposure Prophylaxis (PrEP) With Tailored Messaging to Black Women and Their Healthcare Providers in Texas.

An Early Phase 1 interventional study of Video-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers in HIV Prevention, sponsored by The University of Texas Medical Branch, Galveston. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by The University of Texas Medical Branch, Galveston · Early Phase 1, Interventional, and Prevention

Phase
Early Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

The primary objective of this R34 proposal is to increase willingness for PrEP initiation and PrEP initiation among Black Women (BW) and increase willingness to prescribe/refer pre-exposure prophylaxis (PrEP) to CBW among healthcare providers (HCPs) in Houston/Harris County, a high priority Ending the HIV Epidemic (EHE) jurisdiction.

Read the detailed description

The primary objective of this R34 proposal is to increase willingness for pre-exposure prophylaxis (PrEP) initiation and actual PrEP initiation among BW, increase willingness to prescribe/refer PrEP to BW among HCPs in Houston/Harris County, a high-priority End the HIV Epidemic (EHE) jurisdiction. The investigator hypothesizes that a video-log (vlog) series-based health communication intervention disseminated through community health centers (CHCs) and social media will increase willingness for and use of PrEP among BW. Specifically, the intervention will: 1) encourage BW to access and use PrEP; and 2) increase HCP willingness to prescribe and refer PrEP to BW. Our team will explore two aims: 1) inform and develop health messages for Project ROLE with 2023 findings from focus groups with PrEP-eligible BW and key informant interviews with HCPs providing care to BW, and 2) assess the feasibility, acceptability, and preliminary impact of Project ROLE in two real-world settings with a pilot randomized controlled trial (RCT) and a social media campaign.

Aim 1: A qualitative study using focus groups with Black women and key informant interviews with healthcare providers. (Will not be included in the clinical trial.)

Aim 2a: Pilot randomized controlled trial of a behavioral intervention with both Black women and healthcare providers.

Aim 2b: Social media marketing campaign to reach and engage Black women and healthcare providers in health communication about PrEP. (Will not be included in the clinical trial.)

The proposed research is significant because it will connect Black women to PrEP while increasing healthcare providers willingness to prescribe and refer PrEP to them using a health communication strategy that can guide the development of subsequent vlog-based interventions to address the national EHE plan.

02

Conditions studied

  • HIV Prevention

Keywords

  • Minoritized population
  • Video logs
  • PrEP
  • Health communication
  • Behavioral intervention
03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Selection criteria for participation in pilot RCT.

Eligible participants in the category for Black Women (BW) must:

  1. be a woman
  2. be 18 years of age
  3. have been sexually active with a man within the past 6 months
  4. be fluent in English
  5. have a phone or internet access

Eligible participants (i.e. PrEP-eligible BW) must not:

  1. be unable to provide informed consent/assent for participation (i.e., have severe cognitive impairment hat would interfere with their ability to consent or understand study procedures)
  2. have psychological distress that would prohibit them from participating in the study
  3. be unable or unwilling to meet study requirements
  4. be ineligible for PrEP
  5. received a prescription for PrEP within 12 months6)be unable to fill out the evaluation independently

Eligible participants in the HCP category must:

  1. be a credentialed HCP in Texas with privileges to prescribe and/or refer PrEP
  2. BW must be a part of their patient pool at the clinical setting where they practice clinically
  3. be fluent in English
  4. have a phone or internet access
  5. Live and/or practice medicine within a 60-mile radius of Houston/Harris County

Eligible HCP must not:

  1. be unable to provide informed consent for participation (e.g. have severe cognitive impairment that would interfere with their ability to consent, or ability to understand study procedures
  2. have psychological distress that would prohibit them from participating in the study
  3. be unable or unwilling to meet study requirements
  4. be unwilling to offer PrEP to BW patients
  5. have prescribed or referred PrEP to BW within the last 12 months
04

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will watch a health-informed video-log series and complete a second survey (post-test). The post-test will assess the same variables previously assessed in the pre-test.

    Behavioral: Video-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers

  • No intervention
    Standard of Care

    Participant will receive SOC and complete the post-test.

Interventions

  • BehavioralVideo-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers

    This intervention is a video-log (vlog) series based health communication intervention that will be disseminated through community health centers (CHCs) and social media to increase willingness for and use of PrEP among cisgender Black women and to increase willingness to prescribe and refer PrEP among healthcare providers.

05

What researchers measure

Primary outcomes

  1. Number of participants with increased willingness to access or use PrEP

    To assess whether participation in Project ROLE versus usual care will increase the willingness of Black women to access and/or use PrEP

    Time frame: baseline and day of enrollment and baseline, 1-month, 3-month, and 6-month

  2. Number of healthcare providers increased willingness to prescribe and/or refer PrEP

    To assess whether participation in Project ROLE versus usual care will increase the willingness of healthcare providers to prescribe and/or refer PrEP to Black women

    Time frame: baseline and day of enrollment and baseline, 1-month, 3-month, and 6-month

Secondary outcomes

  1. Number of Black Women started to use of PrEP

    To assess whether Black women started to use PrEP.

    Time frame: 1- month, 3-months, and 6-months follow-up visits

  2. Number of PrEP prescriptions or referrals by healthcare providers

    Using the clinical notes of electronic clinical records at participating CHCs.

    Time frame: 1- month, 3-months, and 6-months follow-up visits

  3. PrEP adherence among those who initiated PrEP

    Assess, using a urine drug screen, whether Black women who initiated PrEP adhered to the PrEP regimen.

    Time frame: 3-months and 6-months follow-up visits

06

Study locations

1 site
  • University of Texas Medical Branch, Galveston
    Galveston, Texas 77555, United States
    • Mandy J. Hill, DrPH · Contact · 409-772-1128
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06864689
Lead sponsor
The University of Texas Medical Branch, Galveston
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Oct 31, 2026 (estimated)
Primary completion
Aug 2, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Mandy Hill, Dr.PH, MPH, HIVPCP
Contact
majhill@utmb.edu
409-266-0509
Mandy Hill, DrPH,MPH,HIVPCP
principal investigator · University of Texas Medical Branch, Galveston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion